Characterization and management of hedgehog pathway inhibitor-related adverse events in patients with advanced basal cell carcinoma

Oncologist

Volumn 21, Issue 10, 2016, Pages 1218-1229

  Lacouture, Mario E ^a   Dréno, Brigitte ^b   Ascierto, Paolo Antonio ^c   Dummer, Reinhard ^d   Basset Seguin, Nicole ^e   Fife, Kate ^f   Ernst, Scott ^g   Licitra, Lisa ^h   Neves, Rogerio I ⁱ   Peris, Ketty ^j   Puig, Susana ^k   Sokolof, Jonas ^a   Sekulic, Aleksandar ^l   Hauschild, Axel ^m   Kunstfeld, Rainer ⁿ  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b HÔTEL DIEU   (France)

^c NATIONAL CANCER INSTITUTE   (Italy)

^d UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^e UNIVERSITÉ PARIS DESCARTES   (France)

^f CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^g LONDON REGIONAL CANCER PROGRAM   (Canada)

^h NATIONAL CANCER INSTITUTE   (Italy)

ⁱ PENN STATE COLLEGE OF MEDICINE   (United States)

^j CATHOLIC UNIVERSITY   (Italy)

^k UNIVERSITY OF BARCELONA   (Spain)

^l MAYO CLINIC   (United States)

^m UNIVERSITY OF KIEL   (Germany)

ⁿ MEDICAL UNIVERSITY OF VIENNA   (Austria)

more..

Author keywords

Advanced basal cell carcinoma; Adverse events; Hedgehog pathway; Management; Sonidegib; Vismodegib

Indexed keywords

AMLODIPINE; DILTIAZEM; GABAPENTIN; PREGABALIN; SONIC HEDGEHOG PROTEIN; SONIDEGIB; VERAPAMIL; VISMODEGIB; ANILIDE; ANTINEOPLASTIC AGENT; BIPHENYL DERIVATIVE; PYRIDINE DERIVATIVE;

ALOPECIA; ARTICLE; ASTHENIA; BASAL CELL CARCINOMA; BASAL CELL NEVUS SYNDROME; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; COMORBIDITY; DIARRHEA; DYSGEUSIA; FATIGUE; HEDGEHOG SIGNALING PATHWAY; HUMAN; LOSS OF APPETITE; MUSCLE SPASM; NAUSEA; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; SIGNAL TRANSDUCTION; SPORTS DRINK; WEIGHT REDUCTION; ANTAGONISTS AND INHIBITORS; CARCINOMA, BASAL CELL; CHEMICALLY INDUCED; DRUG EFFECTS; PHYSIOLOGY; TASTE DISORDER;

ALOPECIA; ANILIDES; ANTINEOPLASTIC AGENTS; ASTHENIA; BIPHENYL COMPOUNDS; CARCINOMA, BASAL CELL; HEDGEHOG PROTEINS; HUMANS; PYRIDINES; SIGNAL TRANSDUCTION; SPASM; TASTE DISORDERS; WEIGHT LOSS;

EID: 84991734849     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2016-0186     Document Type: Article

References (79)

1. Macha MA, Batra SK, Ganti AK. Profile of vismodegib and its potential in the treatment of advanced basal cell carcinoma. Cancer Manag Res 2013;5:197-203.
2. Sekulic A, Mangold AR, Northfelt DW et al. Advanced basal cell carcinoma of the skin: Targeting the hedgehog pathway. Curr Opin Oncol 2013;25: 218-223.
3. Erivedge [package insert]. South San Francisco, CA: Genentech USA, Inc.; 2015.
4. Medicines.co.uk. Erivedge 150 mg hard capsules: Summary of product characteristics. Available at https://http://www.medicines.org.uk/emc/medicine/28107. Accessed April 4, 2016.
5. Migden MR, Guminski A, Gutzmer R et al. Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): A multicentre, randomised, double-blind phase 2 trial. Lancet Oncol 2015;16: 716-728.
6. Sekulic A, Migden MR, Oro AE et al. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med 2012;366:2171-2179.
7. Sekulic A, Migden MR, Lewis K et al. Pivotal ERIVANCE basal cell carcinoma (BCC) study: 12-month update of efficacy and safety of vismodegib in advanced BCC. J Am Acad Dermatol 2015;72: 1021-6.e8.
8. Sekulic A, Migden MR, Basset-Seguin N et al. Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: Final update (30-month) of the pivotal ERIVANCE BCC study. J Clin Oncol 2014;32(suppl):9013a.
9. Chang ALS, Solomon JA, Hainsworth JD et al. Expanded access study of patients with advanced basal cell carcinoma treated with the Hedgehog pathway inhibitor, vismodegib. J AmAcad Dermatol 2014;70:60-69.
10. Lacouture M, Guillen J, Kudchadkar R et al. Management of frequent vismodegib-related adverse events in patients with locally advanced basal cell carcinoma: RegiSONIC Disease Registry Study. Poster presented at the 74th Annual Meeting of the American Academy of Dermatology; March 6, 2016; Washington, DC.
11. Sofen H, Gross KG, Goldberg LH et al. Aphase II, multicenter, open-label, 3-cohort trial evaluating the efficacy and safety of vismodegib in operable basal cell carcinoma. J Am Acad Dermatol 2015;73: 99-105.e1.
12. Basset-Seguin N, Hauschild A, Grob J-J et al. Vismodegib in patients with advanced basal cell carcinoma (STEVIE): A pre-planned interim analysis of an international, open-label trial. Lancet Oncol 2015;16:729-736.
13. Teperino R, Aberger F, Esterbauer H et al. Canonical and non-canonical Hedgehog signalling and the control of metabolism. Semin Cell Dev Biol 2014;33:81-92.
14. Brennan D, Chen X, Cheng L et al. Noncanonical Hedgehog signaling. Vitam Horm 2012;88:55-72.
15. Epstein EH. Basal cell carcinomas: Attack of the hedgehog. Nat Rev Cancer 2008;8:743-754.
16. Göppner D, Leverkus M. Basal cell carcinoma: From the molecular understanding of the pathogenesis to targeted therapy of progressive disease. J Skin Cancer 2011;2011:650258.
17. Lo Muzio L. Nevoid basal cell carcinoma syndrome (Gorlin syndrome). Orphanet J Rare Dis 2008;3:32.
18. Gould SE, Low JA, Marsters JC Jr. et al. Discovery and preclinical development of vismodegib. Expert Opin Drug Discov 2014;9:969-984.
19. Straface G, Aprahamian T, Flex A et al. Sonic hedgehog regulates angiogenesis and myogenesis during post-natal skeletal muscle regeneration. J Cell Mol Med 2009;13(8B):2424-2435.
20. Liu H-X, Ermilov A, Grachtchouk M et al. Multiple Shh signaling centers participate in fungiform papilla and taste bud formation and maintenance. Dev Biol 2013;382:82-97.
21. Yang H, Cong WN, Yoon JS et al. Vismodegib, an antagonist of hedgehog signaling, directly alters taste molecular signaling in taste buds. Cancer Med 2015;4:245-252.
22. Kumari A, Ermilov AN, Allen BL et al. Hedgehog pathway blockade with the cancer drug LDE225 disrupts taste organs and taste sensation. J Neurophysiol 2015;113:1034-1040.
23. St-Jacques B, Dassule HR, Karavanova I et al. Sonic hedgehog signaling is essential for hair development. Curr Biol 1998;8:1058-1068.
24. Chiang C, Swan RZ, Grachtchouk M et al. Essential role for Sonic hedgehog during hair follicle morphogenesis. Dev Biol 1999;205:1-9.
25. Sato N, Leopold PL, Crystal RG. Induction of the hair growth phase in postnatal mice by localized transient expression of Sonic hedgehog. J Clin Invest 1999;104:855-864.
26. Paladini RD, Saleh J, Qian C et al. Modulation of hair growth with small molecule agonists of the hedgehog signaling pathway. J Invest Dermatol 2005;125:638-646.
27. Wang LC, Liu Z-Y, Gambardella L et al. Regular articles: Conditional disruption of hedgehog signaling pathway defines its critical role in hair development and regeneration. J Invest Dermatol 2000;114:901-908.
28. Lear J, Guminski A, Gutzmer R et al. A phase 2, randomized, double-blind studyofsonidegib (LDE225) in patients with advnaced basal cell carcinoma: the BOLT 18-month analysis. Presented at the 24th European Academy of Dermatology and Venereology Congress; October 7-11, 2015; Copenhagen, Denmark.
29. Teperino R, Amann S, Bayer M et al. Hedgehog partial agonism drives Warburg-like metabolism in muscle and brown fat. Cell 2012;151:414-426.
30. Mathias SD, Chren MM, Crosby RD et al. Reliability and validity of the Advanced Basal Cell Carcinoma Index (aBCCdex). Br J Dermatol 2015; 173:713-719.
31. Abdulla AJ, Jones PW, Pearce VR. Leg cramps in the elderly: Prevalence, drug and disease associations. Int J Clin Pract 1999;53:494-496.
32. Bertolasi L, De Grandis D, Bongiovanni LG et al. The influence of muscular lengthening on cramps. Ann Neurol 1993;33:176-180.
33. Pohl C, Happe J, Klockgether T. Cooling improves the writing performance of patients with writer’s cramp. Mov Disord 2002;17:1341-1344.
34. Siegal T. Muscle cramps in the cancer patient: Causes and treatment. J Pain Symptom Manage 1991;6:84-91.
35. Blyton F, Chuter V, Walter KEL et al. Non-drug therapies for lower limb muscle cramps. Cochrane Database Syst Rev 2012;1:CD008496.
36. Ally MS, Tang JY, Lindgren J et al. Effect of calcium channel blockade on vismodegib-induced muscle cramps. JAMA Dermatol 2015;151:1132-1134.
37. Voon W-C, Sheu S-H. Diltiazem for nocturnal leg cramps. Age Ageing 2001;30:91-92.
38. Baltodano N, Gallo BV, Weidler DJ. Verapamil vs quinine in recumbent nocturnal leg cramps in the elderly. Arch Intern Med 1988;148:1969-1970.
39. Serrao M, Rossi P, Cardinali P et al. Gabapentin treatment for muscle cramps: An open-label trial. Clin Neuropharmacol 2000;23:45-49.
40. Sebo P, Cerutti B, Haller DM. Effect of magnesium therapy on nocturnal leg cramps: A systematic review of randomized controlled trials with meta-analysis using simulations. Fam Pract 2014;31:7-19.
41. Prateepavanich P, Kupniratsaikul V, Charoensak T. The relationship between myofascial trigger points of gastrocnemius muscle and nocturnal calf cramps. JMed Assoc Thai 1999;82:451-459.
42. Bedlack RS, Pastula DM, Hawes J et al. Openlabel pilot trial of levetiracetam for cramps and spasticity in patients with motor neuron disease. Amyotroph Lateral Scler 2009;10:210-215.
43. Chan P, Huang T-Y, Chen Y-J et al. Randomized, double-blind, placebo-controlled study of the safety and efficacy of vitamin B complex in the treatment of nocturnal leg cramps in elderly patients with hypertension. J Clin Pharmacol 1998;38:1151-1154.
44. Young JB, Connolly MJ. Naftidrofuryl treatment for rest cramp. Postgrad Med J 1993;69: 624-626.
45. Weil AJ, Ruoff GE, Nalamachu S et al. Efficacy and tolerability of cyclobenzaprine extended release for acute muscle spasm: A pooled analysis. Postgrad Med 2010;122:158-169.
46. Baldinger R, Katzberg HD, Weber M. Treatment for cramps in amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database Syst Rev 2012; 4:CD004157.
47. US Food and Drug Administration. Qualaquin (quinine sulfate):Newriskevaluationandmitigation strategy -risk of serious hematological reactions. Available at http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm218424.htm. AccessedApril 4,2016.
48. Katzberg HD, Khan AH, So YT. Assessment: symptomatic treatment for muscle cramps (an evidence-based review): Report of the therapeutics and technology assessment subcommittee of the American Academy of Neurology. Neurology 2010; 74:691-696.
49. Syrjala KL, Yi JC, Artherholt SB et al. Measuring musculoskeletal symptoms in cancer survivors who receive hematopoietic cell transplantation. J Cancer Surviv 2010;4:225-235.
50. Syrjala KL. MJM (muscle and joint measure). Available at https://http://www.fredhutch.org/content/dam/public/labs-projects/clinical-research/biobehavioral/MJM_updated_1-15-10_Syrjala_et_al_ PDF.pdf. Accessed May 2, 2016.
51. Feng P, Huang L, Wang H. Taste bud homeostasis in health, disease, and aging. Chem Senses 2014;39:3-16.
52. Rawal S, Hoffman HJ, Bainbridge KE et al. Prevalence and risk factors of self-reported smell and taste alterations: Results from the 2011-2012 US National Health and Nutrition Examination Survey (NHANES). Chem Senses 2016;41:69-76.
53. Hovan AJ, Williams PM, Stevenson-Moore P et al. A systematic review of dysgeusia induced by cancer therapies. Support Care Cancer 2010;18: 1081-1087.
54. Gamper E-M, Zabernigg A, Wintner LM et al. Coming to your senses: Detecting taste and smell alterations in chemotherapy patients. A systematic review. J Pain Symptom Manage 2012;44:880-895.
55. Barlow LA. Progress and renewal in gustation: New insights into taste bud development. Development 2015;142:3620-3629.
56. Brisbois TD, de Kock IH, Watanabe SM et al. Delta-9-tetrahydrocannabinol may palliate altered chemosensory perception in cancer patients: Results of a randomized, double-blind, placebo-controlled pilot trial. Ann Oncol 2011;22:2086-2093.
57. Le Moigne M, Saint-Jean M, Jirka A et al. Dysgeusia and weight loss under treatment with vismodegib: Benefit of nutritional management. Support Care Cancer 2016;24:1689-1695.
58. Schiffman SS, Sattely-Miller EA, Taylor EL et al. Combination of flavor enhancement and chemosensory education improves nutritional status in older cancer patients. J Nutr Health Aging 2007;11: 439-454.
59. Heckmann SM, Hujoel P, Habiger S et al. Zinc gluconate in the treatment of dysgeusia-a randomized clinical trial. J Dent Res 2005;84:35-38.
60. Halyard MY, Jatoi A, Sloan JA et al. Does zinc sulfate prevent therapy-induced taste alterations in head and neck cancer patients? Results of phase III double-blind, placebo-controlledtrial fromtheNorth CentralCancerTreatment Group(N01C4). Int JRadiat Oncol Biol Phys 2007;67:1318-1322.
61. Ferguson JS, Hannam S, Toholka R et al. Hair loss and Hedgehog inhibitors: A class effect? Br J Dermatol 2015;173:262-264.
62. Fischer TW, Schmidt S, Strauss B et al. [Hairdex: Atool for evaluation ofdisease-specific quality of life in patients with hair diseases]. Hautarzt 2001;52: 219-227 [article in German].
63. Tang JY, Mackay-Wiggan JM, Aszterbaum M et al. Inhibiting the hedgehog pathway in patients with the basal-cell nevus syndrome. N Engl J Med 2012;366:2180-2188.
64. Alkeraye S, Maire C, Desmedt E et al. Persistent alopecia induced by vismodegib. Br J Dermatol 2015;172:1671-1672.
65. Fearon K, Strasser F, Anker SD et al. Definition and classification of cancer cachexia: An international consensus. Lancet Oncol 2011;12:489-495.
66. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Cancerrelated fatigue.Version 1.2016. Available at http://www.nccn.org/professionals/physician_gls/PDF/fatigue.pdf. Accessed February 2, 2016.
67. National Cancer Institute. Fatigue for health professionals (PDQ). Available at http://www.cancer.gov/about-cancer/treatment/side-effects/fatigue/fatigue-hp-pdq#section/all. Accessed February 2, 2016.
68. Spathis A, Fife K, Blackhall F et al. Modafinil for the treatment of fatigue in lung cancer: Results of a placebo-controlled, double-blind, randomized trial. J Clin Oncol 2014;32:1882-1888.
69. Ruddy KJ, Barton D, Loprinzi CL. Laying to rest psychostimulants for cancer-related fatigue? J Clin Oncol 2014;32:1865-1867.
70. Smets EMA, Garssen B, Bonke B et al. The Multidimensional Fatigue Inventory (MFI) psychometric qualities of an instrument to assess fatigue. J Psychosom Res 1995;39:315-325.
71. Bower JE, Bak K, Berger A et al. Screening, assessment, and management of fatigue in adult survivors of cancer: An American Society of Clinical Oncology clinical practice guideline adaptation. J Clin Oncol 2014;32:1840-1850.
72. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Antiemesis. Version 2.2015. Available at http://www.nccn.org/professionals/physician_gls/pdf/antiemesis.pdf. Accessed February 2, 2016.
73. Russell MC, Cowan RG, Harman RM et al. The hedgehog signaling pathway in the mouse ovary. Biol Reprod 2007;77:226-236.
74. Spicer LJ, Sudo S, Aad PY et al. The hedgehogpatched signaling pathway and function in the mammalian ovary: A novel role for hedgehog proteins in stimulating proliferation and steroidogenesis of theca cells. Reproduction 2009;138:329-339.
75. Sekulic A, Weiss GJ, Solomon JA et al. Amenorrhea or irregular menses in patients treated with vismodegib. Presented at the 2014 Winter Clinical Dermatology Conference; January 17-22, 2014; Kona Coast, HI.
76. Basch E, Reeve BB, Mitchell SA et al. Development of theNational Cancer Institute’s patientreported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). J Natl Cancer Inst 2014;106:dju244.
77. Kunstfeld R, Hauschild A, Zloty D et al. MIKIE: A randomized, double-blind, regimen-controlled, phase II,multicenter study to assess the efficacy and safety of two different vismodegib regimens in patients with multiple basal cell carcinomas. Presented at the 50th Annual Meeting of the American Society of Clinical Oncology; May 30-June 3, 2014; Chicago, IL.
78. Mortier L, Saiag P, Lecca MT et al. A phase II study to assess vismodegib in the neoadjuvant treatment of locally advanced basal cell carcinoma (laBCC): The Vismodegib Neoadjuvant (VISMONEO) study. Presented at the 50th Annual Meeting of the American Society of ClinicalOncology; May30-June 3, 2014; Chicago, IL.
79. Chang ALS, Lewis K, Arron ST et al. Safety and efficacy of vismodegib in elderly patients: analysis of the ERIVANCE BCC and expanded access studies. Presented at the Third Annual World Cutaneous Malignancies Congress; October 29-31, 2014; San Francisco, CA.